PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Li, L.S.* ; Wu, S.* ; Kopp, N.* ; Montero, J.* ; Ryan, J.* ; Chapuy, B.* ; van der Zwet, J.C.* ; Layer, J.* ; Weigert, O. ; Christie, A.L.* ; Christodoulou, A.N.* ; Liu, H.* ; Yoda, A.* ; Hofmann, F.* ; Baffert, F.* ; Vangrevelinghe, E.* ; Gaul, C.* ; Radimerski, T.* ; Letai, A.G.* ; Weinstock, D.M.*

Type II JAK2 inhibitor NVP-CHZ868 is active in vivo against JAK2-dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs).

Blood 124 (2014)
Open Access Green as soon as Postprint is submitted to ZB.
Web of Science
Times Cited
1
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Meeting abstract
Language english
Publication Year 2014
HGF-reported in Year 0
ISSN (print) / ISBN 0006-4971
e-ISSN 1528-0020
Journal Blood
Quellenangaben Volume: 124, Issue: 21 Pages: , Article Number: , Supplement: ,
Publisher American Society of Hematology
Publishing Place Washington
Reviewing status Peer reviewed
Institute(s) CCG Pathogenesis of Acute Myeloid Leukemia (KKG-KPL)
POF-Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Research field(s) Immune Response and Infection
PSP Element(s) G-521000-001
WOS ID WOS:000349242701083
Erfassungsdatum 2015-03-30
[➜Report correction]